VRTX · Full Picture

VERTEX PHARMACEUTICALS INC / MA — the full picture

Earnings window · 2026-07-14 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 79
    +45.5% revenue (realized); 2 sources (news, sec_filing); structured_verified
    ALYFTREK product revenues in Q2 2026: $573.6 million, a 266% increase from $156.8 million in Q2 2025; six months ended ALYFTREK revenues: $998.0 million vs $210.7 million (374% increase)
  2. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 75
    2 sources (news, sec_filing); 3 forward row(s); quote_verified
    Vertex announced a planned acquisition of Crinetics Pharmaceuticals for approximately $10.0 billion to further expand its therapeutic portfolio.
  3. Operating Expense Trends · Operating expenses (SG&A)Priority 73
    -14.0% operating_income (realized); quote_verified
    Recorded an intangible asset impairment charge of $379.0 million associated with VX-264 in the first quarter of 2025
  4. End-Market Demand Trends · Demand, orders & backlogPriority 66
    1 forward row(s); quote_verified
    Approximately 5,500 patients with SCD or TDT may be eligible for treatment with CASGEVY for the first time with this approval
  5. Crinetics Acquisition Financing · M&A and divestituresPriority 65
    1 forward row(s); quote_verified
    Plan to fund the Crinetics acquisition with cash, cash equivalents, and proceeds from the 2026 Term Loan; the acquisition is not conditioned on receipt of financing
  6. Liquidity and Debt Position · Debt, leverage & refinancingPriority 61
    -0.6% liability; 2 forward row(s); quote_verified
    Company expects cash, cash equivalents and current marketable securities together with operating profitability will be sufficient to fund operations for at least the next twelve months
  7. Capital Return Program · Buybacks & dividendsPriority 53
    quote_verified
    As of June 30, 2026, $2.6 billion remaining available under the share repurchase program authorized in May 2025; program has no expiration date
  8. Gross Margin Drivers · Gross marginPriority 50
    -3.3% operating_income (realized); structured_verified
    Cost of sales in Q2 2026: $489.2 million, up 20% from $407.5 million in Q2 2025; cost of sales for six months ended June 30, 2026: $882.0 million, up 14% from $770.5 million
  9. Geographic Market Commentary · Geographic mixPriority 48
    qualitative only
  10. Geographic Revenue Shift · Geographic mixPriority 48
    qualitative only
  11. Guidance / Outlook · Guidance & outlookPriority 47
    1 forward row(s); quote_verified
    Vertex raised its full-year 2026 revenue guidance to $13.1 billion to $13.2 billion.
  12. Regulatory Approval Milestones · Regulatory action & investigationsPriority 45
    2 sources (news, sec_filing); 7 forward row(s); quote_verified
    FDA accepted biologics license application for accelerated approval of povetacicept for adults with IgAN and assigned a PDUFA target action date of November 30, 2026

Threads by pillar

Revenue & Demand Priority 89 · 5 threads

Costs & Margins Priority 80 · 3 threads

Capital & Balance Sheet Priority 73 · 3 threads

Strategy & Portfolio Priority 82 · 3 threads

Legal, Regulatory & Policy Priority 59 · 3 threads

Guidance & Outlook Priority 47 · 1 thread

Macro & Market Conditions Priority 27 · 1 thread

Expected impact by metric

metricforward netforward grossrealized
cash-0.6%+0.6%+7.2%
liability-0.6%+0.6%—
assets——+4.7%
operating_income——-17.4%
net_income——+1.2%
revenue——+45.5%